MATEC Wisconsin in search of a Program Director.

MATEC Wisconsin, located at the University of Wisconsin-Madison, is currently recruiting a Program Director. In support of the Wisconsin office of the Midwest AIDS Training and Education Center (MATEC-WI) and under the direction of the MATEC-WI Clinical Director, the Program Director supervises the planning and implementation of MATEC-WI training and educational programs and activities. They…

Read More

New National Drug Control Strategy Release: HIV-related Impact

The 2022 National Drug Control Strategy was released on April 21, 2022. Over the course of a year, it was developed through requests for written consultations from more than 2,000 external stakeholders, including the entirety of the U.S. Congress; all 50 Governors; and hundreds of advocates representing law enforcement, public health, and Tribal communities. This new Strategy…

Read More

Updated HHS Pediatric Antiretroviral Therapy Guidelines Released

April 12, 2022: The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) has reviewed the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Key updates are summarized below: The U.S. Food and Drug Administration (FDA) recently approved long-acting injectable cabotegravir and rilpivirine (Cabenuva) for use in children and…

Read More

Update to COVID-19 Treatment Guidelines: Changes Affecting People with HIV

February 7, 2022:  The COVID-19 Treatment Guidelines Panel (the Panel) has published a revised version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. The Panel periodically publishes statements that provide up-to-date guidance for clinicians on various aspects of COVID-19 treatment. During this update, the information and recommendations from several recently published statements were incorporated into the…

Read More

Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

February 17, 2022: The Panel updated the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Highlights from the updated section are summarized below:  Mycobacterium tuberculosis Updated references and rationales. Updated drug–drug interactions. Recommended short-course, rifamycin-based, latent tuberculosis infection (LTBI) treatment regimens (3HP and 3HR) over longer isoniazid monotherapy. Clarified that, for the…

Read More

FDA Approves First Injectable Treatment for #HIV Pre-Exposure Prevention (PrEP)

On December 10, 2021, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. Apretude is given first as two initiation injections administered one month apart, and then every…

Read More

Updates to Perinatal HIV Clinical Guidelines

January 5, 2022: The Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission recently updated several sections of the Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. The following sections were among those updated: Maternal HIV Testing and Identification of Perinatal…

Read More